4-(4-Bromo-phenoxy)-2-chloro-pyrimidine | 904961-74-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-Bromo-phenoxy)-2-chloro-pyrimidine
• 英文别名: 4-(4-Bromophenoxy)-2-chloropyrimidine
• CAS: 904961-74-6
• 化学式: C₁₀H₆BrClN₂O
• 分子量: 285.527
• InChiKey: CJTRBYSTEUXIEL-UHFFFAOYSA-N

物化性质

• 沸点：
  398.9±17.0 °C(Predicted)
• 密度：
  1.635±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Bromo-phenoxy)-2-chloro-pyrimidine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以74.4%的产率得到4-(4-Bromo-phenoxy)-2-isopropoxy-pyrimidine
  参考文献：
  名称：

  Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome

  摘要：

  本发明涉及式(I)的化合物，它们抑制乙酰辅酶A羧化酶（ACC），并且对于预防或治疗人类的代谢综合征、2型糖尿病、肥胖、动脉粥样硬化和心血管疾病是有用的。

  公开号：

  US20060178400A1
• 作为产物：
  描述：

  2,4-二氯嘧啶 在 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 反应 3.33h， 以88.6%的产率得到4-(4-Bromo-phenoxy)-2-chloro-pyrimidine
  参考文献：
  名称：

  Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome

  摘要：

  本发明涉及式(I)的化合物，它们抑制乙酰辅酶A羧化酶（ACC），并且对于预防或治疗人类的代谢综合征、2型糖尿病、肥胖、动脉粥样硬化和心血管疾病是有用的。

  公开号：

  US20060178400A1

文献信息

• Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities
  作者：Wei Ming、Wen-Long Lu、Christophe Pannecouque、Jiong Chen、Hai-Feng Wang、Ya-Qi Xiao、Sha Hu、Shuang-Xi Gu、Yuan-Yuan Zhu、Fen-Er Chen

  DOI：10.1016/j.ejmech.2023.115114

  日期：2023.2

  excellent HIV-1 NNRTIs delavirdine and piperidin-4-yl-aminopyrimidine via molecular hybridization. The target compounds 4a-r were prepared and evaluated for their cellular anti-HIV activities and cytotoxicities as well as the inhibitory activities against HIV-1 reverse transcriptase (RT). All the newly synthesized compounds demonstrated moderate to excellent potency against wild-type (WT) HIV-1 with EC50

  地拉韦啶和哌啶-4-基-氨基嘧啶(DPAPY)杂合体是由两种优良的HIV-1 NNRTIs地拉韦啶和哌啶-4-基-氨基嘧啶通过分子杂交设计而成。制备了目标化合物4a-r，并评估了其细胞抗HIV活性和细胞毒性以及对HIV-1逆转录酶（RT）的抑制活性。所有新合成的化合物均表现出中等至优异的抗野生型 (WT) HIV-1 效力，EC 50值在 5.7 至 0.0086 μM 范围内，而对抗 RT，IC 50值在 12.0 至 0.11 μM 范围内，表明 DPAPY是特异性 RT 抑制剂。其中，4d显示出针对 WT HIV-1 的最有效活性（EC 50  = 8.6 nM，SI = 2151）。令人欣慰的是，它对单一 HIV-1 突变体 L100I、K103N、Y181C、Y188L、E138K 以及双突变体 F227L + V106A 表现出良好至优异的效力。此外，还总结了初步的构效关系，并
• Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities
  作者：Ting Xiao、Jia-Fan Tang、Ge Meng、Christophe Pannecouque、Yuan-Yuan Zhu、Gen-Yan Liu、Zhi-Qiang Xu、Feng-Shou Wu、Shuang-Xi Gu、Fen-Er Chen

  DOI：10.1016/j.ejmech.2019.111864

  日期：2020.1

  A series of indazolyl-substituted piperidin-4-yl-aminopyrimidines (IPAPYs) were designed from two potent HIV-1 NNRTIs piperidin-4-yl-aminopyrimidine 3c and diaryl ether 4 as the lead compounds by molecular hybridization strategy. The target molecules 5a-q were synthesized and evaluated for their anti-HIV activities and cytotoxicities in MT-4 cells. 5a-q displayed moderate to excellent activities against wild-type (WT) HIV-1 with ECK values ranging from 1.5 to 0.0064 mu M. Among them, 5q was regarded as the most excellent compound against WT HIV-1 (EC50 = 6.4 nM, SI = 2500). And also, it displayed potent activities against K103 N (EC50 = 0.077 mu M), Y181C (EC50 = 0.11 mu M), E138K (EC50 = 0.057 mu M), and moderate activity against double mutants RES056 (EC50 = 8.7 mu M). Moreover, the structure-activity relationships (SARs) were summarized, and the molecular docking was performed to investigate the binding mode of IPAPYs and HIV-1 reverse transcriptase. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
  申请人：Beutel A. Bruce

  公开号：US20060178400A1

  公开（公告）日：2006-08-10

  The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

  本发明涉及式(I)的化合物，它们抑制乙酰辅酶A羧化酶（ACC），并且对于预防或治疗人类的代谢综合征、2型糖尿病、肥胖、动脉粥样硬化和心血管疾病是有用的。